Could a common diuretic protect hearts in rare ARVD?
NCT ID NCT03593317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether spironolactone, a potassium-sparing diuretic, can slow the deterioration of the right ventricle and reduce arrhythmias in people with arrhythmogenic right ventricular dysplasia (ARVD). About 120 participants will receive either spironolactone or a placebo for 12 months, with follow-up over 3 years. The goal is to see if this drug can improve quality of life and reduce hospitalizations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
spironolactone
What this could lead to
If it works, this could point toward a treatment that slows heart muscle damage and reduces dangerous heart rhythms in people with ARVD.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. Spironolactone may not slow disease progression or reduce arrhythmias as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens Picardie
NOT_YET_RECRUITINGAmiens, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU Dijon
RECRUITINGDijon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Groupe Hospitalo Universitaire Caremeau
NOT_YET_RECRUITINGNîmes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Arnaud de Villeneuve
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Cardiologique Louis Pradel
RECRUITINGBron, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Gabriel Montpied
NOT_YET_RECRUITINGClermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Laennec
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Michallon
NOT_YET_RECRUITINGGrenoble, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Pitié Salpetrière
RECRUITINGParis, France
Contact
Contact Email: •••••@•••••
-
Hôpital Rangueil
NOT_YET_RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital de Haut-Lévêque
NOT_YET_RECRUITINGPessac, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital de la Timone
NOT_YET_RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nouvel Hôpital Civil
NOT_YET_RECRUITINGStrasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact